<DOC>
	<DOCNO>NCT00002357</DOCNO>
	<brief_summary>To obtain preliminary information safety , tolerability , antiretroviral activity HBY 097 alone combination zidovudine ( AZT ) versus AZT alone . PER 1/19/96 AMENDMENT : AZT monotherapy arm eliminate .</brief_summary>
	<brief_title>The Safety Effectiveness HBY 097 Used With Without AZT HIV-Infected Patients Who Have Mild No Symptoms</brief_title>
	<detailed_description>Patients randomize receive one three dos HBY 097 without AZT AZT alone 12 week ( AZT monotherapy arm eliminate per 1/19/96 amendment ) . All patient give dose level HBY 097 must enrol adequate safety data obtain escalation subsequent patient begin . Additional patient enter optimal dose HBY 097 . Patients evaluate weekly first 4 week every 2 week next 9 week . PER AMENDMENT : Enrollment low dose cohort complete .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Treatment opportunistic infection develop study . Recommended : PCP prophylaxis CD4 count fall 200 cells/mm3 . Patients must : HIV infection . CD4 count 200 500 cells/mm3 . HIV1 RNA PCR value 10000 copies/ml high . Asymptomatic mildly symptomatic disease . No past current AIDSdefining event . Consent parent guardian less legal age consent . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Endocrine , hepatic , renal , gastrointestinal disease . Cardiovascular conduction disease . Concomitant medical illness may complicate study conduct interpretation result . Other factor may interfere patient compliance . Concurrent Medication : Excluded : Antiretroviral agent study drug . Oral contraceptive . Cytotoxic chemotherapy . Immunomodulators . Antiproliferative agent . Corticosteroids . Anabolic steroid . Estrogens . Quinoxaline derivative . Concurrent Treatment : Excluded : Radiation therapy . Patients follow prior condition exclude : History hypersensitivity quinoxaline derivative intolerance AZT . History cardiovascular conduction disease . Prior participation study study use HBY 097 . Recent use drug interferes drug metabolism , absorption , distribution , excretion . History thyroid disease . Prior Medication : Excluded time : Prior nonnucleoside reverse transcriptase inhibitor . Excluded within 30 day prior study entry : Any antiretroviral therapy . Oral contraceptive . Immunomodulating agent systemic corticosteroid , interleukin , interferon . Cytotoxic chemotherapeutic agent . Other investigational drug . Excluded within 6 month prior study entry : Immunotherapeutic vaccine . Prior Treatment : Excluded within 30 day prior study entry : Radiation therapy . An experimental device . Current ethanol illicit drug abuse .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 1997</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Zidovudine</keyword>
</DOC>